SnyderF.Platelet-activating factor and related acetylated lipids as potent biological acting cellular mediators. Am J Physiol1990; 259: 697.
2.
CamussiG.Tetta C, Baglioni C. The role of platelet-activating factor in inflammation. Clin Immun Immunopath1990; 57: 331.
3.
SchtondorffD., NeuwirthR.Platelet-activating factor and the kidney. Am J Physiol1986; 251: F1.
4.
MontrucchioG., BergeroneS., BussolinoF.Streptokinase induces intravascular release of platelet-activating factor and prostacyclin in patients with actue myocardial infarction and stimulates its synthesis by cultured endothelial cells. Circulation1993; 88: 1476.
5.
MandrenasJ., Pintos MorellG., BratolomeE.PAF-acether (platelet-activating factor) and biocomptibility of hemodialysis membranes. Kidney Int1987; 32: 614.
6.
Gonzalez-LopezA., Fernandez-GallardoS., CaramelaC., InarreaP., HernandoL., Sanchez CrespoM.Presence of PAF-acether in blood during hemodialysis (HD) and its relation with dialysis leukopenia. Kidney Int1985; 28: 587.
7.
CristolJ.P., CanaudB., DamonM., ChavisC., ArnouxB., MionC.Platelet-activating factor production during hemodialysis: effect of BN 52021. Prostaglandins-Leukot-Essent. Fatty Acids1992; 45: 37.
8.
SakaguchiK., MorimotoS., ChenJ-H, NakamotoY., OgiharaT.Increase in circulating level of platelet-activating factor lag behind transient neutropemia during hemodialysis with cupraphan membrane. Nephron1991; 59: 445.
9.
TettaC., DavidS., BianconeL.Role of platelet-activating factor in hemodialysis. Kidney Int1993; 43: 514.
10.
IarrouC., AfenkatisN., AntonopoulouS.The production of platelet-activating factor (PAF) during hemodialysis with cuprophan membrane. Does the calcium concentration in the dialysate play any role on it? Int J Artif Organs1995; 18: 355–61.
11.
TielemansC., MadhounP., LenaersM.Anaphylactoid reactions during hemodialysis on AN-69 membranes in patients receiving ACE inhibitors. Kidney Int1990; 38: 982.
12.
Alvarez-LaraM.A., Martin-MaloA., EspinozaM., CastilloD., AlfamaP.ACE inhibitors and anaphylactoid reactions to high-flux membrane dialysis (Letter). Lancet1991; 337: 370.
13.
JadoulM., StuyvenJ., StragierA., Van Ypersele de StrihouC.Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis (Letter). Lancet1991; 337: 112.
14.
ParnesEl, ShapiroW.B.Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int1991; 40: 114S.
HakimR.M., BreillattJ., LazarusJ.M., PortF.K.Complement activation and hypersensitivity reactions to dialysis membrane. N Engl J Med1984; 311: 878.
17.
VerresenL., FinkE., LemkeH.D.Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int1994; 45: 1497.
18.
BhoolaK.D., FigueroaC.D., WorthyK.Bioregulation of kinase kallikreins, kininogens and kininases. Pharmacol Rev1992; 44: 1.
19.
Mc IntyreT.M., ZimmermanG.A., SatohK., PrescottS.M.Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin and adenosine triphosphate. J Clin Invest1985; 76: 271.
20.
MannstadtM., TonamM., FinkE.No generation of bradykinin with a new PAN membrane (SPAN) in dialysis patients treated with ACE inhibitors. EDTA. Athens Abstracts Book1995; 248.
21.
TettaC., BussolinoF., ModenaV.Release of platelet-activating factor in Systemic Lupus Erythematosus. Int Arch Allergy Appl Immunol1990; 91: 241.
MathewsJ.N.S., HoenichN.A.Statistical aspects of the design and analysis of studies to compare hemodialysis membranes. Nephrol Dial Transplant1994; 9(Suppl 2): 176.
24.
TettaC., SegoloniG., PacittiA., CamussiC., VercelloneA.The production of platelet-activating factor in hemodialysis. Int J Artif Organs1989; 12: 766.
25.
RoncoC., TettaC.Lupi A, et al. Removal of platelet-activating factor in experimental continuous arteriovenous hemofiltration. Crit Care Med1995; 23: 99.
26.
Van der NiepenP., SennesaelJ.J., VerbeelenD.L.Kinin kinetics during different dialysis protocols with AN69 dialyser in ACEI. Treatet patients. Nephrol Dial Transplant1995; 10: 1689.
